Neoprobe Corporation (OTC BB: NEOP) has focused their efforts on developing and commercializing novel biomedical products that address the critical intraoperative, diagnostic and therapeutic treatment needs of patients and physicians. The company’s main area of dedication is on improving cancer surgery outcomes by utilizing their market-leading gamma detection devices in conjunction with radiopharmaceutical agents.
- 17 years ago
QualityStocks
Neoprobe Corporation (OTC BB: NGNM)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – XTI Aerospace, Inc. (NASDAQ: XTIA) Highlights Revenue Visibility and Operating Leverage at Shareholder Town Hall
XTI Aerospace (NASDAQ: XTIA), an aerospace technology company focused on scaling its Drone Nerds, LLC subsidiary,…
-
Safe Pro Group Inc. (NASDAQ: SPAI) Will Highlight the Company’s AI Capabilities for Military Engineers at Upcoming 2026 Defence Leaders Combat Engineer & Logistics Conference
Safe Pro Group will present at the 2026 Defence Leaders Combat Engineer & Logistics Conference…
-
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment
LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system This…